Annual CFI
N/A
December 31, 2024
Summary
- PRLD annual cash flow from investing activities is not available.
Performance
PRLD Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFI
N/A
December 31, 2024
Summary
- PRLD quarterly cash flow from investing activities is not available.
Performance
PRLD Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFI
N/A
December 31, 2024
Summary
- PRLD TTM cash flow from investing activities is not available.
Performance
PRLD TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
PRLD Cash From Investing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | - | - | - |
3 y3 years | - | - | - |
5 y5 years | - | - | - |
PRLD Cash From Investing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | ||||||
5 y | 5-year | ||||||
alltime | all time |
Prelude Therapeutics Incorporated Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $10.73 M(-58.9%) | $75.81 M(-5.4%) |
Jun 2024 | - | $26.12 M(-16.3%) | $80.12 M(-474.0%) |
Mar 2024 | - | $31.22 M(+303.6%) | -$21.42 M(-38.2%) |
Dec 2023 | -$34.65 M(-142.4%) | $7.74 M(-48.6%) | -$34.65 M(-15.6%) |
Sep 2023 | - | $15.04 M(-119.9%) | -$41.03 M(+19.0%) |
Jun 2023 | - | -$75.43 M(-519.1%) | -$34.47 M(-159.3%) |
Mar 2023 | - | $18.00 M(+1228.3%) | $58.14 M(-28.8%) |
Dec 2022 | $81.69 M | $1.35 M(-93.7%) | $81.69 M(+4.0%) |
Sep 2022 | - | $21.61 M(+25.8%) | $78.53 M(-138.6%) |
Jun 2022 | - | $17.18 M(-58.6%) | -$203.71 M(-7.9%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | $41.55 M(-2403.1%) | -$221.27 M(-16.1%) |
Dec 2021 | -$263.80 M(>+9900.0%) | -$1.80 M(-99.3%) | -$263.80 M(+0.6%) |
Sep 2021 | - | -$260.63 M(>+9900.0%) | -$262.33 M(>+9900.0%) |
Jun 2021 | - | -$381.00 K(-61.4%) | -$1.87 M(+22.2%) |
Mar 2021 | - | -$986.00 K(+199.7%) | -$1.53 M(+145.9%) |
Dec 2020 | -$621.00 K(-20.4%) | -$329.00 K(+93.5%) | -$621.00 K(+112.7%) |
Sep 2020 | - | -$170.00 K(+304.8%) | -$292.00 K(+139.3%) |
Jun 2020 | - | -$42.00 K(-47.5%) | -$122.00 K(+52.5%) |
Mar 2020 | - | -$80.00 K | -$80.00 K |
Dec 2019 | -$780.00 K(+47.4%) | - | - |
Dec 2018 | -$529.00 K | - | - |
FAQ
- What is the all time high annual CFI for Prelude Therapeutics Incorporated?
- What is the all time high quarterly CFI for Prelude Therapeutics Incorporated?
- What is the all time high TTM CFI for Prelude Therapeutics Incorporated?
What is the all time high annual CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual cash flow from investing activities is $81.69 M
What is the all time high quarterly CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly cash flow from investing activities is $41.55 M
What is the all time high TTM CFI for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM cash flow from investing activities is $81.69 M